Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 4,445 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 4,445 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $7.45, for a total transaction of $33,115.25. Following the completion of the transaction, the executive vice president owned 129,799 shares in the company, valued at approximately $967,002.55. The trade was a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vir Biotechnology Stock Up 27.7%

Shares of VIR stock opened at $9.49 on Wednesday. The firm has a market cap of $1.32 billion, a P/E ratio of -3.00 and a beta of 1.69. The company has a 50 day moving average of $6.80 and a 200-day moving average of $5.99. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.29.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.The business had revenue of $64.07 million during the quarter, compared to analyst estimates of $19.91 million. During the same period in the prior year, the company earned ($0.76) earnings per share. Vir Biotechnology’s revenue was up 417.8% compared to the same quarter last year. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on VIR. Evercore reiterated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Morgan Stanley lifted their price target on Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday, December 30th. Finally, Needham & Company LLC raised their target price on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $19.88.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in VIR. ARCH Venture Management LLC purchased a new position in Vir Biotechnology during the second quarter worth about $65,100,000. GSK plc bought a new stake in shares of Vir Biotechnology during the 4th quarter valued at about $51,562,000. State Street Corp grew its holdings in shares of Vir Biotechnology by 18.9% during the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after purchasing an additional 988,262 shares in the last quarter. Orbimed Advisors LLC increased its position in shares of Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after purchasing an additional 132,466 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Vir Biotechnology by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock valued at $14,041,000 after purchasing an additional 81,985 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.